North America Point Of Care Diagnostics Market Size | Companies
The North America point of care diagnostics market size was exhibited at USD 18.85 billion in 2023 and is projected to hit around USD 34.73 billion by 2033, growing at a CAGR of 6.3% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 20.04 Billion |
| Market Size by 2033 | USD 34.73 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 6.3% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Product, End-use, Type, Country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | U.S., Canada |
| Key Companies Profiled | F. Hoffmann-La Roche AG; QIAGEN; Danaher Corporation; BD; bioMérieux SA; Abbott; Siemens Healthineers A.G.; Zoetis, Inc.; Instrumentation Laboratory; Nova Biomedical; Trividia Health, Inc.; Quidel Corporation; Trinity Biotech; Sekisui Diagnostics; OraSure Technologies, Inc.; NIPRO, Spectral Medical, Inc. |
Point-of-care (POC) diagnosis refers to performing diagnostic tests at the site of the patient. The growing geriatric population and the ability of POC diagnostic tests to deliver immediate results are likely to fuel the demand for POC diagnostic tests. Furthermore, a rise in funding from the government & private institutions is a key factor driving the market’s growth. An increase in the adoption of mobile diagnostic devices in the region is also one of the key factors driving demand for POC testing.
The COVID-19 outbreak has positively impacted the market. This can primarily be attributed to the urgent need for manufacturing and introduction of rapid & portable diagnostic tests, systems, and accessories in the market that can presently assist in scaling up of COVID-19 testing. Moreover, the advent of rapid data-sharing platforms and solutions is expected to contribute to the development of COVID-19 point-of-care technologies, supplementing the market growth. Companies are actively working toward the development of rapid testing solutions. For instance, in November 2023, Sense Biodetection entered into a collaboration with Bio Nuclear Diagnostics to distribute Sense’s Veros POC, an instrument-free molecular COVID-19 test, in Canada.
Furthermore, increased funding from NIH, private foundations such as the Bill & Melinda Gates Foundation, and the U.S. department of defense (DOD), is anticipated to fuel the market growth. For instance, in November 2021, Hyperfine, Inc., announced receiving USD 3.3 million in funding from the Bill & Melinda Gates Foundation to broaden the usage of portable MRI technology in various countries. Similarly, in August 2023, Nanopath, Inc. received funding of USD 10 million from Medtech Convergence Fund and Norwest Venture Partners with participation from Green D Ventures and Gingerbread Capital. The funding would help develop point-of-care diagnostics for women’s health.
In the U.S., the population aged 65 and older is estimated to double from 52 million in 2018 to 95 million by 2060, which is likely to increase demand for POC diagnostics. According to projections, there will be a 23% increase in the overall population. Aging increases the risk of diseases such as cardiovascular diseases and cancer. Therefore, an increase in the geriatric population is expected to boost the demand for continuous monitoring via facilities requiring point-of-care diagnostics, such as home healthcare and assisted living healthcare facilities.
The infectious diseases segment accounted for 25.3% of the total market share in 2023, owing to increasing cases of dengue fever, enteric, malaria, syphilis, tuberculosis, and others in the region. The significant demand for rapid tests has encouraged market players to offer point-of-care solutions to decentralized regions. For instance, in March 2020, Abbott launched a molecular POC test that could detect the presence of coronavirus in less than five minutes.
The cardiac markers segment is anticipated to witness the fastest CAGR in the coming years owing to due to increase in acceptance of sensitivity and premium-priced POC Troponin testing. The growing trend toward value-based and efficient healthcare service delivery, along with stringent finances, is strengthening the market for point-of-care cardiac diagnostics.Furthermore, in emergency care settings, the majority of medical professionals prefer POC cardiac testing to monitor the state of patients experiencing chest discomfort or other heart illness symptoms.
The hospitals segment dominated the North America point-of-care diagnostics market in 2023, capturing a revenue share of 37.68%. POC is beneficial for healthcare personnel as it provides mobility to the diagnosis system and allows reaching patients effectively. The development of wireless communication and miniaturized devices is a boon for hospital-based POC diagnostics as these provide single-level access throughout the hospital.
The laboratories segment is projected to witness the fastest growth during the forecast period owing to the rise in the need for early identification of many diseases. In addition, each year, more than 7 billion clinical laboratory examinations are performed in the U.S., as per an article published by the American Clinical Laboratory Association. The market is predicted to increase due to the presence of a strong distribution network of companies, such as Quest Diagnostics Incorporated, Siemens Healthineers, Laboratory Corporation of America Holdings, and Abbott, among others.
The POC devices that are developed have different medical diagnostic applications, such as cancer, infectious diseases, and pregnancy. Physicians& patients use POC tests to screen diseases, confirm diagnoses, and design suitable therapeutic approaches based on the patient’s health. For instance, in July 2020, BD launched a portable, Rapid POC Antigen Test which detects COVID-19 infection within 15 minutes. It has expanded access to COVID-19 testing.
The LDT segment is anticipated to witness the fastest growth rate in the coming years with a CAGR of 6.2%. Laboratory-developed tests are testing services developed in patient care at clinical laboratories, academics, and hospitals. These services are not commercially marketed and manufactured, but are developed, performed, designed, validated, and interpreted by certified professionals in a laboratory. These are used to meet clinical demands and are instrumental for early diagnosis, monitoring, and guidance of patient treatment.
The U.S. dominated the North America point-of-care market in 2023 due to the presence of key players such as Abbott, BIOMERIEUX, BD, Siemens Healthineers AG, QIAGEN, Quidel Corporation, and Quest Diagnostics is positively influencing the market growth. For instance, in November 2020, in the U. S., QIAGEN started offering a portable digital test that allows labs to detect SARS-CoV-2 antigens in persons with current illnesses in 2 to 15 minutes.
Canada is estimated to witness the fastest growth rate over the coming years. Usage of POC diagnostic devices in these regions is increasing owing to the increasing prevalence of target diseases such as cardio-metabolic disorders, infectious diseases, and increasing cases of drug abuse. Increasing demand for rapid and early diagnosis leading to better treatment alternatives and presence of health-conscious population are also considered as other factors fueling industrial growth. People in this region are also shifting their focus towards self-testing devices as compared to frequent laboratory testing visits, thus influencing industrial growth.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the North America point of care diagnostics market
Product
End-use
Type
Country
Chapter 1 Methodology And Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Research Methodology
1.4 Definitions
1.5 Information Procurement
1.5.1 Purchased Database
1.5.2 Internal Database
1.5.3 Secondary Sources
1.5.4 Primary Research
1.5.5 Details Of Primary Research
1.6 Information Or Data Analysis
1.6.1 Market Categorization
1.6.2 Point - Of - Care Testing
1.6.2.1 Poc - End - Use Penetration Mapping
1.6.3 Data Analysis Models
1.7 Market Formulation & Validation
1.8 Model Details
1.8.1 Commodity Flow Analysis
1.8.1.1 Approach 1: Commodity Flow Approach
1.8.1.2 Approach 2: Country - Wise Market Estimation Using The Bottom - Up Approach
1.9 North America Market: Cagr Calculation
1.10 List Of Secondary Sources
1.11 List Of Primary Sources
1.12 Objectives
1.12.1 Objective 1:
1.12.2 Objective 2:
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Market Summary
2.3 Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Market Variables, Trends, And Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.1.3 Molecular Technology Intervention
3.1.3.1 Key Factors Considered For Analyzing Molecular Technology Interventions Across Point-Of-care (Poc) Testing
3.2 Penetration And Growth Prospect Mapping For Poc Products, 2022
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Introduction Of Clia - Waived Tests
3.3.1.2 Rise In Funding From Government And Private Institutions
3.3.1.3 Growing Geriatric Population
3.3.1.4 Growing Prevalence Of Targeted Diseases
3.3.1.5 Growing Demand For Home Healthcare And Introduction Of Advanced Technology - Enabled Products
3.3.2 Market Restraint Analysis
3.3.2.1 Presence Of Ambiguous Regulatory Framework
3.3.3 Market Challenge Analysis
3.3.3.1 Poc Devices Pose Challenges In Maintaining Quality Standards
3.3.4 Market Opportunity Analysis
3.3.4.1 Networking & Remote Access Integration Of Poc Diagnostics Products
3.3.4.1.1 Smartphone Orientation
3.3.4.1.2 Embedded Vision - Based Solutions
3.3.4.1.3 Digital Technologies
3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.5 Industry Analysis - Porter’s
3.6 Market Entry Strategies
3.7 Price - Cost - Margin Analysis For Poc Testing
3.8 User Perspective Analysis
3.8.1 Consumer Behavior Analysis
3.9 Technology Overview
3.10 Poc Diagnostics: Market Influencers
3.10.1 High Sensitivity
3.10.2 Shift To Molecular Diagnostics
3.10.3 Glucose Testing
3.10.4 Hba1c Testing
3.10.5 Coagulation Testing
3.10.6 Fertility Testing
3.10.7 Infectious Disease
3.10.8 Cardiac Markers
3.10.9 Thyroid - Stimulating Hormone
3.10.10 Hematology
3.10.11 Primary Care Systems
3.10.12 Decentralized Clinical Chemistry
3.10.13 Feces
3.10.14 Lipid Testing
3.10.15 Cancer Marker
3.10.16 Blood Gas/Electrolytes
3.10.17 Ambulatory Chemistry
3.10.18 Drug Of Abuse (Doa) Testing
3.10.19 Urinalysis
3.11 Covid - 19 Impact Analysis
3.12 Overview
3.12.1 Covid - 19 Point - Of - Care Diagnostics: Technology Overview
3.12.2 Covid - 19 Point - Of - Care Diagnostics: Regulatory Overview
3.12.3 Covid - 19 Point - Of - Care Diagnostics: Competitive Landscape
Chapter 4 Product Business Analysis
4.1 North America Point - Of - Care (Poc) Diagnostics Market: Product Movement Analysis
4.2 Glucose Testing
4.2.1 Glucose Testing Market Estimates And Forecast, 2021 - 2033
4.2.2 Glucose Testing Market, By End - Use
4.2.2.1 Glucose Testing Market, By Hospital
4.2.2.2 Glucose Testing Market, By Laboratories
4.2.2.3 Glucose Testing Market, By Home Care
4.2.2.4 Glucose Testing Market, By Clinic
4.2.2.5 Glucose Testing Market, By Physician Office
4.2.2.6 Glucose Testing Market, By Pharmacy & Retail Clinics
4.2.2.7 Glucose Testing Market, By Non - Practice Clinics
4.2.2.8 Glucose Testing Market, By Urgent Care Clinics
4.2.2.9 Glucose Testing Market, By Others
4.2.2.10 Glucose Testing Market, By Rural Health Clinic
4.2.2.11 Glucose Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.2.3 Glucose Testing Market, By Disease
4.2.3.1 Diabetes
4.2.3.2 Glucose Testing Market, By Diabetes
4.2.3.3 Others
4.2.3.4 Glucose Testing Market, By Others
4.3 Hba1c Testing
4.3.1 Hba1c Testing Market Estimates And Forecast, 2021 - 2033
4.3.2 Hba1c Testing Market, By End - Use
4.3.2.1 Hba1c Testing Market, By Hospital
4.3.2.2 Hba1c Testing Market, By Laboratories
4.3.2.3 Hba1c Testing Market, By Home Care
4.3.2.4 Hba1c Testing Market, By Clinic
4.3.2.5 Hba1c Testing Market, By Physician Office
4.3.2.6 Hba1c Testing Market, By Pharmacy & Retail Clinics
4.3.2.7 Hba1c Testing Market, By Non - Practice Clinics
4.3.2.8 Hba1c Testing Market, By Urgent Care Clinics
4.3.2.9 Hba1c Testing Market, By Others
4.3.2.10 Hba1c Testing Market, By Rural Health Clinic
4.3.2.11 Hba1c Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.3.3 Hba1c Testing Market, By Disease
4.3.3.1 Diabetes
4.3.3.2 Hba1c Testing Market, By Diabetes
4.3.3.3 Others
4.3.3.4 Hba1c Testing Market, By Others
4.4 Coagulation Testing
4.4.1 Coagulation Testing Market Estimates And Forecast, 2021 - 2033
4.4.2 Coagulation Testing Market, By End - Use
4.4.2.1 Coagulation Testing Market, By Hospital
4.4.2.2 Coagulation Testing Market, By Laboratories
4.4.2.3 Coagulation Testing Market, By Home Care
4.4.2.4 Coagulation Testing Market, By Clinic
4.4.2.5 Coagulation Testing Market, By Physician Office
4.4.2.6 Coagulation Testing Market, By Pharmacy & Retail Clinics
4.4.2.7 Coagulation Testing Market, By Non - Practice Clinics
4.4.2.8 Coagulation Testing Market, By Urgent Care Clinics
4.4.2.9 Coagulation Testing Market, By Others
4.4.2.10 Coagulation Testing Market, By Rural Health Clinic
4.4.2.11 Coagulation Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.4.3 Coagulation Testing Market, By Disease
4.4.3.1 Thrombosis
4.4.3.2 Coagulation Testing Market, By Thrombosis
4.4.3.3 Hemophilia
4.4.3.4 Coagulation Testing Market, By Hemophilia
4.4.3.5 Others
4.4.3.6 Coagulation Testing Market, By Others
4.5 Fertility/Pregnancy
4.5.1 Fertility/Pregnancy Market Estimates And Forecast, 2021 - 2033
4.5.2 Fertility Testing Market, By End - Use
4.5.2.1 Fertility Testing Market, By Hospital
4.5.2.2 Fertility Testing Market, By Laboratories
4.5.2.3 Fertility Testing Market, By Home Care
4.5.2.4 Fertility Testing Market, By Clinic
4.5.2.5 Fertility Testing Market, By Physician Office
4.5.2.6 Fertility Testing Market, By Pharmacy & Retail Clinics
4.5.2.7 Fertility Testing Market, By Non - Practice Clinics
4.5.2.8 Fertility Testing Market, By Urgent Care Clinics
4.5.2.9 Fertility Testing Market, By Others
4.5.2.10 Fertility Testing Market, By Rural Health Clinic
4.5.2.11 Fertility Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.5.3 Fertility Testing Market, By Type
4.5.3.1 Lh - Ovulation Elite Tes
4.5.3.2 Fertility Testing Market, By Lh - Ovulation Elite Test
4.5.3.3 Hcg - Pregnancy Tests
4.5.3.4 Fertility Testing Market, By Hcg - Pregnancy Tests
4.5.3.5 Fertility Tests
4.5.3.6 Fertility Testing Market, By Fertility Tests
4.5.3.7 Others
4.5.3.8 Fertility Testing Market, By Others
4.6 Infectious Disease Testing
4.6.1 Infectious Disease Testing Market Estimates And Forecast, 2021 - 2033
4.6.2 Infectious Disease Testing Market, By End - Use
4.6.2.1 Infectious Disease Testing Market, By Hospital
4.6.2.2 Infectious Disease Testing Market, By Laboratories
4.6.2.3 Infectious Disease Testing Market, By Home Care
4.6.2.4 Infectious Disease Testing Market, By Clinic
4.6.2.5 Infectious Disease Testing Market, By Physician Office
4.6.2.6 Infectious Disease Testing Market, By Pharmacy & Retail Clinics
4.6.2.7 Infectious Disease Testing Market, By Non - Practice Clinics
4.6.2.8 Infectious Disease Testing Market, By Urgent Care Clinics
4.6.2.9 Infectious Disease Testing Market, By Others
4.6.2.10 Infectious Disease Testing Market, By Rural Health Clinic
4.6.2.11 Infectious Disease Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.6.3 Infectious Disease Testing Market, By Disease
4.6.3.1 Hiv Poc
4.6.3.2 Infectious Disease Testing Market, By Hiv Poc
4.6.3.3 Clostridium Difficile Poc
4.6.3.4 Infectious Disease Testing Market, By Clostridium Difficile Poc
4.6.3.5 Hbv Poc
4.6.3.6 Infectious Disease Testing Market, By Hbv Poc
4.6.3.7 Pneumonia Or Streptococcus - Associated Infections
4.6.3.8 Infectious Disease Testing Market, By Pneumonia Or Streptococcus Associated Infections
4.6.3.9 Respiratory Syncytial Virus Poc
4.6.3.10 Infectious Disease Testing Market, By Respiratory Syncytial Virus (Rsv) Poc
4.6.3.11 Hpv Poc
4.6.3.12 Infectious Disease Testing Market, By Hpv Poc
4.6.3.13 Influenza/Flu Poc
4.6.3.14 Infectious Disease Testing Market, By Influenza/Flu Poc
4.6.3.15 Hcv Poc
4.6.3.16 Infectious Disease Testing Market, By Hcv Poc
4.6.3.17 Mrsa Poc
4.6.3.18 Infectious Disease Testing Market, By Mrsa Poc
4.6.3.19 Tb And Drug - Resistant Tb Poc
4.6.3.20 Infectious Disease Testing Market, By Tb And Drug - Resistant Tb Poc
4.6.3.21 Hsv Poc
4.6.3.22 Infectious Disease Testing Market, By Hsv Poc
4.6.3.23 Covid - 19
4.6.3.24 Infectious Disease Testing Market, By Covid - 19
4.6.3.25 Other Infectious Diseases
4.6.3.26 Infectious Disease Testing Market, By Other Infectious Diseases
4.7 Cardiac Markers
4.7.1 Cardiac Markers Market Estimates And Forecast, 2021 - 2033
4.7.2 Cardiac Markers Market, By End - Use
4.7.2.1 Cardiac Markers Market, By Hospital
4.7.2.2 Cardiac Markers Market, By Laboratories
4.7.2.3 Cardiac Markers Market, By Home Care
4.7.2.4 Cardiac Markers Market, By Clinic
4.7.2.5 Cardiac Markers Market, By Physician Office
4.7.2.6 Cardiac Markers Market, By Pharmacy & Retail Clinics
4.7.2.7 Cardiac Markers Market, By Non - Practice Clinics
4.7.2.8 Cardiac Markers Market, By Urgent Care Clinics
4.7.2.9 Cardiac Markers Market, By Others
4.7.2.10 Cardiac Markers Market, By Rural Health Clinic
4.7.2.11 Cardiac Markers Market, By Federally Qualified Health Clinic (Fqhc)
4.7.3 Cardiac Markers Market, By Disease
4.7.3.1 Acute Coronary Syndrome
4.7.3.2 Cardiac Markers Market, By Acute Coronary Syndrome
4.7.3.3 Myocardial Infarction
4.7.3.4 Cardiac Markers Market, By Myocardial Infarction
4.7.3.5 Congestive Heart Failure
4.7.3.6 Cardiac Markers Market, By Congestive Heart Failure
4.7.3.7 Others
4.7.3.8 Cardiac Markers Market, By Others
4.7.4 Cardiac Markers Market, By Marker
4.8 Thyroid Stimulating Hormone
4.8.1 Thyroid Stimulating Hormone Market Estimates And Forecast, 2021 - 2033
4.8.2 Thyroid Stimulating Hormone Market, By End - Use
4.8.2.1 Thyroid Stimulating Hormone Market, By Hospital
4.8.2.2 Thyroid Stimulating Hormone Market, By Laboratories
4.8.2.3 Thyroid Stimulating Hormone Market, By Home Care
4.8.2.4 Thyroid Stimulating Hormone Market, By Clinic
4.8.2.5 Thyroid Stimulating Hormone Market, By Physician Office
4.8.2.6 Thyroid Stimulating Hormone Market, By Pharmacy & Retail Clinics
4.8.2.7 Thyroid Stimulating Hormone Market, By Non - Practice Clinics
4.8.2.8 Thyroid Stimulating Hormone Market, By Urgent Care Clinics
4.8.2.9 Thyroid Stimulating Hormone Market, By Others
4.8.2.10 Thyroid Stimulating Hormone Market, By Rural Health Clinic
4.8.2.11 Thyroid Stimulating Hormone Market, By Federally Qualified Health Clinic (Fqhc)
4.8.3 Thyroid Stimulating Hormone Market, By Disease
4.8.3.1 Hyperthyroidism
4.8.3.2 Thyroid Stimulating Hormone Market, By Hyperthyroidism
4.8.3.3 Hypothyroidism
4.8.3.4 Thyroid Stimulating Hormone Market, By Hypothyroidism
4.9 Hematology
4.9.1 Hematology Market Estimates And Forecast, 2021 - 2033
4.9.2 Hematology Market, By End - Use
4.9.2.1 Hematology Market, By Hospital
4.9.2.2 Hematology Market, By Laboratories
4.9.2.3 Hematology Market, By Home Care
4.9.2.4 Hematology Market, By Clinic
4.9.2.5 Hematology Market, By Physician Office
4.9.2.6 Hematology Market, By Pharmacy & Retail Clinics
4.9.2.7 Hematology Market, By Non - Practice Clinics
4.9.2.8 Hematology Market, By Urgent Care Clinics
4.9.2.9 Hematology Market, By Others
4.9.2.10 Hematology Market, By Rural Health Clinic
4.9.2.11 Hematology Market, By Federally Qualified Health Clinic (Fqhc)
4.9.3 Hematology Market, By Disease
4.9.3.1 Anemia
4.9.3.2 Hematology Market, By Anemia
4.9.3.3 Leukemia
4.9.3.4 Hematology Market, By Leukemia
4.9.3.5 Others
4.9.3.6 Hematology Market, By Others
4.10 Primary Care Systems
4.10.1 Primary Care Systems Market Estimates And Forecast, 2021 - 2033
4.10.2 Primary Care Systems Market, By End - Use
4.10.2.1 Primary Care Systems Market, By Hospital
4.10.2.2 Primary Care Systems Market, By Laboratories
4.10.2.3 Primary Care Systems Market, By Home Care
4.10.2.4 Primary Care Systems Market, By Clinic
4.10.2.5 Primary Care Systems Market, By Physician Office
4.10.2.6 Primary Care Systems Market, By Pharmacy & Retail Clinics
4.10.2.7 Primary Care Systems Market, By Non - Practice Clinics
4.10.2.8 Primary Care Systems Market, By Urgent Care Clinics
4.10.2.9 Primary Care Systems Market, By Others
4.10.2.10 Primary Care Systems Market, By Rural Health Clinic
4.10.2.11 Primary Care Systems Market, By Federally Qualified Health Clinic (Fqhc)
4.11 Decentralized Clinical Chemistry
4.11.1 Decentralized Clinical Chemistry Market Estimates And Forecast, 2021 - 2033
4.11.2 Decentralized Clinical Chemistry Market, By End - Use
4.11.2.1 Decentralized Clinical Chemistry Market, By Hospital
4.11.2.2 Decentralized Clinical Chemistry Market, By Laboratories
4.11.2.3 Decentralized Clinical Chemistry Market, By Home Care
4.11.2.4 Decentralized Clinical Chemistry Market, By Clinic
4.11.2.5 Decentralized Clinical Chemistry Market, By Physician Office
4.11.2.6 Decentralized Clinical Chemistry Market, By Pharmacy & Retail Clinics
4.11.2.7 Decentralized Clinical Chemistry Market, By Non - Practice Clinics
4.11.2.8 Decentralized Clinical Chemistry Market, By Urgent Care Clinics
4.11.2.9 Decentralized Clinical Chemistry Market, By Others
4.11.2.10 Decentralized Clinical Chemistry Market, By Rural Health Clinic
4.11.2.11 Decentralized Clinical Chemistry Market, By Federally Qualified Health Clinic (Fqhc)
4.12 Feces
4.12.1 Feces Point - Of - Care (Poc) Diagnostics Market Estimates And Forecast, 2021 - 2033
4.12.2 Feces Market, By End - Use
4.12.2.1 Feces Market, By Hospital
4.12.2.2 Feces Market, By Laboratories
4.12.2.3 Feces Market, By Home Care
4.12.2.4 Feces Market, By Clinic
4.12.2.5 Feces Market, By Physician Office
4.12.2.6 Feces Market, By Pharmacy & Retail Clinics
4.12.2.7 Feces Market, By Non - Practice Clinics
4.12.2.8 Feces Market, By Urgent Care Clinics
4.12.2.9 Feces Market, By Others
4.12.2.10 Feces Market, By Rural Health Clinic
4.12.2.11 Feces Market, By Federally Qualified Health Clinic (Fqhc)
4.12.3 Feces Market, By Disease
4.12.3.1 Colorectal Cancer
4.12.3.2 Feces Market, By Colorectal Cancer
4.12.3.3 Gi Disorders
4.12.3.4 Feces Market, By Gi Disorders
4.12.3.5 Others
4.12.3.6 Feces Market, By Others
4.13 Lipid Testing
4.13.1 Lipid Market Estimates And Forecast, 2021 - 2033
4.13.2 Lipid Testing Market, By End - Use
4.13.2.1 Lipid Testing Market, By Hospital
4.13.2.2 Lipid Testing Market, By Laboratories
4.13.2.3 Lipid Testing Market, By Home Care
4.13.2.5 Lipid Testing Market, By Physician Office
4.13.2.6 Lipid Testing Market, By Pharmacy & Retail Clinics
4.13.2.7 Lipid Testing Market, By Non - Practice Clinics
4.13.2.8 Lipid Testing Market, By Urgent Care Clinics
4.13.2.9 Lipid Testing Market, By Others
4.13.2.9.1 Lipid Testing Market, By Rural Health Clinic
4.13.2.9.2 Lipid Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.13.3 Lipid Testing Market, By Disease
4.13.3.1 Hyperlipidemia
4.13.3.1.1 Lipid Testing Market, By Hyperlipidemia
4.13.3.2 Cardiovascular Diseases
4.13.3.2.1 Lipid Testing Market, By Cardiovascular Diseases
4.13.3.3 Others
4.13.3.3.1 Lipid Testing Market, By Others
4.14 Cancer Marker
4.14.1.1 Cancer Marker Market Estimates And Forecast, 2021 - 2033
4.14.2 Cancer Marker Market, By End - Use
4.14.2.1 Cancer Marker Market, By Hospital
4.14.2.2 Cancer Marker Market, By Laboratories
4.14.2.3 Cancer Marker Market, By Home Care
4.14.2.4 Cancer Marker Market, By Clinic
4.14.2.5 Cancer Marker Market, By Physician Office
4.14.2.6 Cancer Marker Market, By Pharmacy & Retail Clinics
4.14.2.7 Cancer Marker Market, By Non - Practice Clinics
4.14.2.8 Cancer Marker Market, By Urgent Care Clinics
4.14.2.9 Cancer Marker Market, By Others
4.14.2.10 Cancer Marker Market, By Rural Health Clinic
4.14.2.11 Cancer Marker Market, By Federally Qualified Health Clinic (Fqhc)
4.14.3 Cancer Marker Market, By Disease
4.14.3.1 Breast Cancer
4.14.3.2 Cancer Marker Market, By Breast Cancer
4.14.3.3 Prostate Cancer
4.14.3.4 Cancer Marker Market, By Prostate Cancer
4.14.3.5 Colorectal Cancer
4.14.3.6 Cancer Marker Market, By Colorectal Cancer
4.14.3.7 Kidney Cancer
4.14.3.8 Cancer Marker Market, By Kidney Cancer
4.14.3.9 Lung Cancer
4.14.3.10 Cancer Marker Market, By Lung Cancer
4.14.3.11 Bladder Cancer
4.14.3.12 Cancer Marker Market, By Bladder Cancer
4.14.3.13 Other Cancer
4.14.3.14 Cancer Marker Market, By Other
4.14.4 Cancer Marker Market, By Marker
4.14.5 Blood Gas/Electrolytes
4.14.5.1 Blood Gas/Electrolytes Market Estimates And Forecast, 2021 - 2033
4.14.6 Blood Gas/Electrolytes Market, By End - Use
4.14.6.1 Blood Gas/Electrolytes Market, By Hospital
4.14.6.2 Blood Gas/Electrolytes Market, By Laboratories
4.14.6.3 Blood Gas/Electrolytes Market, By Home Care
4.14.6.4 Blood Gas/Electrolytes Market, By Clinic
4.14.6.5 Blood Gas/Electrolytes Market, By Physician Office
4.14.6.6 Blood Gas/Electrolytes Market, By Pharmacy & Retail Clinics
4.14.6.7 Blood Gas/Electrolytes Market, By Non - Practice Clinics
4.14.6.8 Blood Gas/Electrolytes Market, By Urgent Care Clinics
4.14.6.9 Blood Gas/Electrolytes Market, By Others
4.14.6.10 Blood Gas/Electrolytes Market, By Rural Health Clinic
4.14.6.11 Blood Gas/Electrolytes Market, By Federally Qualified Health Clinic (Fqhc)
4.14.7 Ambulatory Chemistry
4.14.7.1 Ambulatory Chemistry Market Estimates And Forecast, 2021 - 2033
4.14.8 Ambulatory Chemistry Market, By End - Use
4.14.8.1 Ambulatory Chemistry Market, By Hospital
4.14.8.2 Ambulatory Chemistry Market, By Laboratories
4.14.8.3 Ambulatory Chemistry Market, By Home Care
4.14.8.4 Ambulatory Chemistry Market, By Clinic
4.14.8.5 Ambulatory Chemistry Market, By Physician Office
4.14.8.6 Ambulatory Chemistry Market, By Pharmacy & Retail Clinics
4.14.8.7 Ambulatory Chemistry Market, By Non - Practice Clinics
4.14.8.8 Ambulatory Chemistry Market, By Urgent Care Clinics
4.14.8.9 Ambulatory Chemistry Market, By Others
4.14.8.10 Ambulatory Chemistry Market, By Rural Health Clinic
4.14.8.11 Ambulatory Chemistry Market, By Federally Qualified Health Clinic (Fqhc)
4.14.9 Drug Abuse Testing
4.14.9.1 Drug Abuse Testing Market Estimates And Forecast, 2021 - 2033
4.14.10 Drug Of Abuse (Doa) Testing Market, By End - Use
4.14.10.1 Drug Of Abuse (Doa) Testing Market, By Hospital
4.14.10.2 Drug Of Abuse (Doa) Testing Market, By Laboratories
4.14.10.3 Drug Of Abuse (Doa) Testing Market, By Home Care
4.14.10.4 Drug Of Abuse (Doa) Testing Market, By Clinic
4.14.10.5 Drug Of Abuse (Doa) Testing Market, By Physician Office
4.14.10.6 Drug Of Abuse (Doa) Testing Market, By Pharmacy & Retail Clinics
4.14.10.7 Drug Of Abuse (Doa) Testing Market, By Non - Practice Clinics
4.14.10.8 Drug Of Abuse (Doa) Testing Market, By Urgent Care Clinics
4.14.10.9 Drug Of Abuse (Doa) Testing Market, By Others
4.14.10.10 Drug Of Abuse (Doa) Testing Market, By Rural Health Clinic
4.14.10.11 Drug Of Abuse (Doa) Testing Market, By Federally Qualified Health Clinic (Fqhc)
4.14.11 Urinalysis
4.14.11.1 Urinalysis Market Estimates And Forecast, 2021 - 2033
4.14.12 Urinalysis/Nephrology Market, By End - Use
4.14.12.1 Urinalysis/Nephrology Market, By Hospital
4.14.12.2 Urinalysis/Nephrology Market, By Laboratories
4.14.12.3 Urinalysis/Nephrology Market, By Home Care
4.14.12.4 Urinalysis/Nephrology Market, By Clinic
4.14.12.5 Urinalysis/Nephrology Market, By Physician Office
4.14.12.6 Urinalysis/Nephrology Market, By Pharmacy & Retail Clinics
4.14.12.7 Urinalysis/Nephrology Market, By Non - Practice Clinics
4.14.12.8 Urinalysis/Nephrology Market, By Urgent Care Clinics
4.14.12.9 Urinalysis/Nephrology Market, By Others
4.14.12.10 Urinalysis/Nephrology Market, By Rural Health Clinic
4.14.12.11 Urinalysis/Nephrology Market, By Federally Qualified Health Clinic (Fqhc)
4.14.13 Urinalysis/Nephrology Market, By Disease
4.14.13.1 Uti
4.14.13.2 Urinalysis/Nephrology Market, By Uti
4.14.13.3 Kidney Disease
4.14.13.4 Urinalysis/Nephrology Market, By Kidney Disease
4.14.13.5 Diabetes
4.14.13.6 Urinalysis/Nephrology Market, By Diabetes
4.14.13.7 Others
4.14.13.8 Urinalysis/Nephrology Market, By Others
Chapter 6 End - Use Business Analysis
6.1 North America Point - Of - Care Diagnostics Market: End - Use Movement Analysis
6.1.1 Clinics
6.1.1.1 Clinics Market Estimates And Forecast, 2021 - 2033
6.1.1.2 Pharmacy & Retail Clinics
6.1.1.2.1 Pharmacy & Retail Clinics Market Estimates And Forecast, 2021 - 2033
6.1.1.3 Physician Office
6.1.1.3.1 Physician Office Market Estimates And Forecast, 2021 - 2033
6.1.1.4 Urgent Care Clinics
6.1.1.4.1 Urgent Care Clinics Market Estimates And Forecast, 2021 - 2033
6.1.1.5 Non - Practice Clinics
6.1.1.5.1 Non - Practice Clinics Market Estimates And Forecast, 2021 - 2033
6.1.1.6 Others
6.1.1.6.1 Others Market Estimates And Forecast, 2021 - 2033
6.1.1.6.2 Rural Health Clinic
6.1.1.6.2.1 Rural Health Clinic Market Estimates And Forecast, 2021 - 2033
6.1.1.6.3 Federally Qualified Health Clinic (Fqhc)
6.1.1.6.3.1 Federally Qualified Health Clinic Market Estimates And Forecast, 2021 - 2033
6.1.2 Hospitals
6.1.2.1 Hospitals Market Estimates And Forecast, 2021 - 2033
6.1.3 Home Care
6.1.3.1 Home Care Market Estimates And Forecast, 2021 - 2033
6.1.3.2 Self - Testing
6.1.3.2.1 Self - Testing Market For Self - Testing, 2021 - 2033
6.1.3.3 Self - Collection
6.1.3.4 Self - Collection Market For Self - Collection Facilities, 2021 - 2033
6.1.4 Laboratories
6.1.4.1 Laboratories Market For Laboratory, 2021 - 2033
Chapter 7 Type Business Analysis
7.1 North America Point - Of - Care Diagnostics Market: Type Movement Analysis
7.1.1 Ldt
7.1.1.1 Ldt Market Estimates And Forecast, 2021 - 2033
7.1.2 Other Poc
7.1.2.1 Other Poc Market Estimates And Forecast, 2021 - 2033
Chapter 8 North America Poc Diagnostics Market: Regional Estimates And Trend Analysis, By Product, Type, & End - Use, And Location
8.1 North America
8.1.1 Swot Analysis:
8.1.1.1 North America Poc Market Estimates And Forecasts, 2021 - 2033
8.1.2 U.S.
8.1.2.1 Key Country Dynamics
8.1.2.2 Research And Development Statistics
8.1.2.3 Competitive Scenario
8.1.2.4 Regulatory Framework
8.1.2.5 Reimbursement Scenario
8.1.2.6 U.S. Poc Market Estimates And Forecasts, 2021 - 2033
8.1.3 Canada
8.1.3.1 Key Country Dynamics
8.1.3.2 Target Disease Prevalence
8.1.3.3 Competitive Scenario
8.1.3.4 Regulatory Framework
8.1.3.5 Reimbursement Scenario
8.1.3.6 Canada Poc Market Estimates And Forecasts, 2021 - 2033
Chapter 9 Competitive Landscape
9.1 Recent Developments & Impact Analysis, By Key Market Participants
9.2 Vendor Landscape
9.2.1 Key Distributors Marketing Channels
9.2.2 Market Leaders, Emerging Companies, And Key Innovators
9.2.2.1 Abbott Diagnostics
9.2.2.2 Abbott Diagnostics: Marketing Channels & Distribution Network For Poc
9.2.2.3 Alere, Inc.
9.2.2.4 Alere, Inc.: Marketing Channels & Distribution Network For Poc
9.2.2.5 Roche Diagnostics
9.2.2.6 Roche Diagnostics: Marketing Channels & Distribution Network For Poc
9.2.2.7 Siemens Healthineers
9.2.2.8 Siemens Healthineers: Marketing Channels & Distribution Network For Poc
9.2.2.9 Danaher Corporation
9.2.2.10 Danaher Corporation: Marketing Channels & Distribution Network For Poc
9.2.2.11 Instrumentation Laboratory Spa
9.2.2.12 Instrumentation Laboratory Spa.: Marketing Channels & Distribution Network For Poc
9.2.2.13 Becton Dickinson
9.2.2.14 Becton Dickinson.: Marketing Channels & Distribution Network For Poc
9.2.3 Key Customers
9.3 Company Market Positioning Analysis, 2021
9.3.1 Glucose Monitoring
9.3.2 Cardiac Markers
9.3.3 Hematology
9.3.4 Coagulation
9.3.5 Fertility Testing
9.3.6 Infectious Diseases
9.3.7 Decentralized Clinical Chemistry
9.3.8 Oncology Markers
9.3.9 Blood Gas Testing
9.3.10 Ambulatory Chemistry
9.3.11 Drugs Of Abuse
9.3.12 Urinalysis
9.4 Key Parameters
9.4.1 Company Size
9.4.2 Geographic Presence And Distribution Network
9.4.3 Product Portfolio
9.4.4 Collaborations
9.5 Competitive Dashboard Analysis
9.6 Market Differentiators
9.6.1 Application Trends
9.6.2 Technology Trends
9.6.3 Test Location Trends
9.6.4 End - Use Trends
9.6.5 Regional Trends
9.7 Private Companies
9.7.1 New Entrants/Emerging Players
9.8 Product Market Share, 2021
9.9 Participant’s Overview
9.10 Financial Performance
9.11 Participant Categorization
9.11.1 Market Leaders
9.11.1.1 North America Poc Market Share Analysis, 2022
9.11.2 Strategy Mapping
9.11.2.1 Expansion
9.11.2.2 Acquisition
9.11.2.3 Partnership
9.11.2.4 Product/Service Launch
9.11.2.5 Others F. Hoffmann-La Roche AG
9.11.2.5.1 QIAGEN
9.11.2.5.2 Danaher Corporation
9.11.2.5.3 BD
9.11.2.5.4 bioMérieux SA
9.11.2.5.5 Abbott
9.11.2.5.6 Siemens Healthineers A.G.
9.11.2.5.7 Zoetis, Inc.
9.11.2.5.8 Instrumentation Laboratory
9.11.2.5.9 Nova Biomedical
9.11.2.5.10 Trividia Health, Inc.
9.11.2.5.11 Quidel Corporation
9.11.2.5.12 Trinity Biotech
9.11.2.5.13 Sekisui Diagnostics
9.11.2.5.14 OraSure Technologies, Inc.
9.11.2.5.15 NIPRO
9.11.2.5.16 Spectral Medical, Inc.
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers